We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
HGH (Somatropin)is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most HGH (Somatropin) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 1990–2014 with a typical study size of 131 participants.
Based on 7 studies · 1 meta-analysis · 2 RCTs · 3,648 total participants
Confidence
ModerateBy outcome
HGH (Somatropin) has an evidence score of 4.2/10 — emerging evidence based on 7 indexed studies, including 3 meta-analyses. Recombinant human growth hormone — the classic performance and 'anti-aging' hormone. FDA-approved as a prescription injectable ONLY for growth-hormone deficiency and a handful of other conditions, where replacement reliably improves body composition. But its anti-aging and athletic reputation OUTSTRIPS the evidence: in healthy older adults and athletes, randomized trials and systematic reviews (Liu 2007/2008) show only small body-composition changes, NO functional or strength benefit, and MORE adverse events — edema, arthralgia, carpal tunnel, and impaired glucose tolerance. Distributing or using it for anti-aging or sport is illegal in the US, and it is NOT a dietary supplement. This is a gated harm-reduction reference, not a recommendation. Representative study: PMID 21865409.
The commonly studied dose of HGH (Somatropin) is Prescription-only and clinician-directed — this is a hormone drug, NOT a self-administered supplement, and we do not provide a non-medical dosing protocol. For context only: replacement for diagnosed adult GH deficiency is individualized and titrated to a clinical and IGF-1 target, typically starting low (e.g. ~0.2–0.4 mg/day subcutaneously) and adjusted. The anti-aging and athletic doses used illicitly are far higher, illegal, and carry the metabolic, fluid, joint, and organomegaly harms documented here — not a regimen this library endorses.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Recombinant human growth hormone (somatropin)
Recombinant human growth hormone — the classic performance and 'anti-aging' hormone. FDA-approved as a prescription injectable ONLY for growth-hormone deficiency and a handful of other conditions, where replacement reliably improves body composition. But its anti-aging and athletic reputation OUTSTRIPS the evidence: in healthy older adults and athletes, randomized trials and systematic reviews (Liu 2007/2008) show only small body-composition changes, NO functional or strength benefit, and MORE adverse events — edema, arthralgia, carpal tunnel, and impaired glucose tolerance. Distributing or using it for anti-aging or sport is illegal in the US, and it is NOT a dietary supplement. This is a gated harm-reduction reference, not a recommendation.
For diagnosed growth-hormone deficiency the replacement evidence is real and randomized — a 54-RCT meta-analysis (Hazem 2012) shows GH reduces fat, increases lean mass, and improves quality of life. But that is the approved, indication-bounded use. The famous anti-aging and performance reputation OUTSTRIPS the evidence: the Liu systematic reviews (2007 in the healthy elderly, 2008 in athletes) found only small body-composition changes, NO functional/strength benefit, and MORE adverse events, concluding GH cannot be recommended as anti-aging therapy and that performance claims are unsupported. Rudman 1990 and Blackman 2002 showed body-composition change but, in Blackman, a high adverse-event burden including diabetes. The athletic signal (Meinhardt 2010) was a small, fluid-driven sprint gain that vanished after stopping. It is a prescription drug — not a supplement — and distributing/using it for anti-aging or sport is illegal; it impairs glucose tolerance, causes edema/arthralgia/carpal tunnel, and carries organomegaly and cancer/mortality concerns.
Human growth hormone (GH, somatropin) is a 191-amino-acid pituitary hormone, now manufactured as recombinant human GH, that drives postnatal growth and regulates adult body composition and metabolism.
It acts both directly on tissues and, more importantly, by stimulating the liver to produce insulin-like growth factor 1 (IGF-1), the main mediator of its anabolic effects; GH itself is also directly lipolytic, promoting fat breakdown.
As a prescription drug, recombinant GH has genuine, approved uses: it is FDA-approved for childhood and adult growth-hormone deficiency, Turner syndrome, Prader-Willi syndrome, chronic renal insufficiency in children, short stature in certain conditions, and AIDS-associated wasting.
In adults with confirmed GH deficiency the replacement evidence is real and randomized — a systematic review and meta-analysis of 54 RCTs (Hazem 2012) found GH reduced weight and body-fat content, increased lean body mass, and improved quality of life in most trials, at the cost of more edema and joint stiffness.
That is the legitimate, indication-bounded case. The rest of GH's fame is the problem this entry exists to correct.
Its reputation as an anti-aging and physique/performance drug rests largely on Daniel Rudman's small 1990 New England Journal of Medicine study, in which six months of GH in men over 60 increased lean body mass by about 9% and decreased fat mass by about 14% — a body-composition signal that launched a multi-billion-dollar 'anti-aging' industry, even though Rudman's own later commentary and the NEJM editors warned the result was being misused.
When the question was tested rigorously, the anti-aging story collapsed.
The Blackman 2002 JAMA randomized trial in healthy older men and women found GH (with or without sex steroids) did increase lean mass and reduce fat, but produced little or no gain in strength or endurance in women, only marginal strength gains in men, and a high burden of adverse effects — edema, carpal tunnel symptoms, arthralgias, and notably diabetes or glucose intolerance (18 GH-treated men vs 7 not on GH).
The decisive evidence is Hauashia Liu's two systematic reviews in the Annals of Internal Medicine: the 2007 review of GH in the healthy elderly concluded GH causes only small body-composition changes, increases adverse events (soft-tissue edema, arthralgias, carpal tunnel syndrome, gynecomastia, and a trend to diabetes/impaired fasting glucose), and 'cannot be recommended as an antiaging therapy'; the 2008 review of GH and athletic performance concluded that claims GH enhances physical performance 'are not supported by the scientific literature' — lean mass rose but strength and exercise capacity did not, and exercise capacity may even worsen.
The one athletic signal, from the WADA-funded Meinhardt 2010 randomized trial, was a small (~4%) increase in sprint capacity that was largely water-driven (lean-mass gain was extracellular water), did not improve strength, power, or VO2max, and disappeared within six weeks of stopping.
So across healthy older adults and athletes, the honest picture is: modest, largely fluid-mediated body-composition change with no proven functional benefit, bought with a meaningful rise in adverse events. The harms are not trivial.
GH antagonizes insulin and reliably impairs glucose tolerance and can precipitate diabetes; it causes fluid retention (edema), arthralgias, and carpal tunnel syndrome; chronic GH excess (as in acromegaly) causes organomegaly — the so-called 'GH gut'/visceral and organ enlargement physique seen in heavy users — cardiomyopathy, and is associated with increased mortality and cancer concern, which is why GH/IGF-1 axis stimulation is avoided in active malignancy and why long-term safety of non-deficient use is genuinely uncertain.
Legally and definitionally this matters: GH is a prescription drug, not a dietary supplement; the US Anti-Substance Abuse provisions make it a federal crime to distribute or possess GH for any use other than the specific FDA-approved indications, so the anti-aging and bodybuilding markets are explicitly illegal, and GH is banned in sport by WADA at all times.
The score reflects this split: real, randomized, approved benefit for diagnosed GH deficiency (body composition, quality of life), against an anti-aging reputation that the best evidence — the Liu systematic reviews — actively refutes, an athletic benefit that is minimal and fluid-driven, documented metabolic, fluid, joint, and organ harms, and an illegal, prescription-only legal status.
HGH is a hormone drug, not a supplement, and not a validated anti-aging or performance agent.
Somatropin binds the growth-hormone receptor, most importantly on the liver, stimulating production of insulin-like growth factor 1 (IGF-1) — the principal mediator of GH's anabolic effects on lean tissue and bone.
GH acts directly on adipose tissue to promote lipolysis (fat breakdown), driving the reduction in fat mass seen in trials — a GH effect that is partly independent of IGF-1.
GH antagonizes insulin action and promotes sodium/water retention. The same axis that builds lean mass also impairs glucose tolerance, causes edema and arthralgia, and in chronic excess (acromegaly) drives organomegaly — the core dose-dependent harms.
How HGH (Somatropin) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Prescription-only and clinician-directed — this is a hormone drug, NOT a self-administered supplement, and we do not provide a non-medical dosing protocol. For context only: replacement for diagnosed adult GH deficiency is individualized and titrated to a clinical and IGF-1 target, typically starting low (e.g. ~0.2–0.4 mg/day subcutaneously) and adjusted. The anti-aging and athletic doses used illicitly are far higher, illegal, and carry the metabolic, fluid, joint, and organomegaly harms documented here — not a regimen this library endorses.
Can be taken without food
| Form | Type |
|---|---|
| 💊Clinician-prescribed somatropin (subcutaneous injection) for a diagnosed, approved indication — prescription-only hormone drug | Recommended |
| 💊Treating the underlying cause of low GH/IGF-1 rather than supplementing the hormone | Alternative |
| 💊GHRH analogues / GH secretagogues (e.g. sermorelin) are sometimes marketed as 'natural' GH boosters, but their anti-aging benefit is equally unproven | Alternative |
Form and route are a medical decision. There is no over-the-counter or dietary-supplement form of HGH; pills and sprays sold as 'HGH' or 'HGH releasers' do not contain bioavailable growth hormone.
Minimum: 12 weeks
Optimal: 26 weeks
Cycling: Not required
Note: Clinician-directed and titrated to IGF-1 and clinical response — not a fixed supplement schedule. Replacement is usually a daily evening/bedtime subcutaneous injection (or weekly for long-acting products).
Dose-response data unavailable. The current published research for HGH (Somatropin) does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
In adults with confirmed GH deficiency, replacement reliably reduces fat mass, increases lean body mass, and improves quality of life in most trials — the legitimate, approved use.
In healthy older adults (Rudman 1990, Blackman 2002), GH raises lean body mass and lowers fat — but the lean-mass gain is largely extracellular water, not the functional muscle the reputation implies.
Systematic reviews (Liu 2007, Liu 2008) found GH does NOT improve strength, exercise capacity, or function in healthy elderly or athletes; the small sprint gain in Meinhardt 2010 was fluid-driven and vanished after stopping. GH 'cannot be recommended as an antiaging therapy.'
Even in trials, GH increased soft-tissue edema, arthralgias, carpal tunnel syndrome, gynecomastia, and impaired glucose tolerance/diabetes (18 vs 7 GH-treated men in Blackman 2002). Chronic excess causes organomegaly ('GH gut') and cardiac effects.
This is the indication the RCT/meta-analysis evidence supports. Replacement under an endocrinologist, titrated to IGF-1, improves body composition and quality of life — not a performance or longevity intervention.
Not supported. The Liu 2007 systematic review found only small body-composition change with more adverse events and concluded GH cannot be recommended as an anti-aging therapy.
Caution — GH impairs glucose tolerance and can precipitate diabetes. Glucose and HbA1c need monitoring, and GH is generally avoided where glycemic control is poor.
Avoid — GH/IGF-1 axis stimulation is a theoretical proliferation risk and GH is contraindicated with active malignancy.
Prohibited by WADA at all times. The proven athletic effect is a small, fluid-driven sprint change with no strength/endurance benefit (Meinhardt 2010); using it risks an anti-doping violation and is illegal.
Avoid — not established as safe; not an approved use.
GH antagonizes insulin and impairs glucose tolerance, often raising insulin/antidiabetic dose requirements; it can precipitate diabetes or worsen glycemic control.
GH can reduce conversion of cortisone to cortisol and unmask central hypoadrenalism; glucocorticoid replacement dosing may need adjustment, and supraphysiologic glucocorticoids blunt GH's growth-promoting effect.
Tip: GH antagonizes insulin; in Blackman 2002, 18 of the GH-treated men vs 7 not on GH developed diabetes or glucose intolerance. Monitor fasting glucose/HbA1c, especially in older or overweight users.
Tip: A dose-dependent, fluid-mediated effect that also explains much of the 'lean mass' gain. Usually improves with dose reduction; more common in older adults and at higher doses.
Tip: Joint pain/stiffness and carpal tunnel symptoms were significantly more frequent on GH in the systematic reviews and Blackman 2002; reduce dose or stop if they occur.
Tip: Reported more often in GH-treated participants in the healthy-elderly systematic review; usually reversible on stopping.
The best time to take HGH (Somatropin) is before bed. It can be taken on an empty stomach. Replacement regimens are usually dosed once daily by evening/bedtime subcutaneous injection to approximate the physiologic overnight GH pulse, then titrated by a clinician to IGF-1 and clinical response — not a fixed supplement schedule.
HGH (Somatropin) should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are impaired glucose tolerance / new-onset diabetes, soft-tissue edema / fluid retention, arthralgia, joint stiffness & carpal tunnel syndrome. Use caution if any of these apply to you: Use without a prescription / without medical supervision — GH is prescription-only and illegal to distribute or use for anti-aging or sport in the US; Active or suspected malignancy (GH/IGF-1 axis stimulation is a proliferation concern); Active proliferative or severe non-proliferative diabetic retinopathy.
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Tap node to isolate • Pinch to zoom • Tap edge for research
Oral estrogen reduces the IGF-1 response to GH (higher GH doses may be needed), and GH can unmask central hypothyroidism, altering thyroid-hormone requirements.
GH can increase CYP-mediated clearance, potentially lowering levels of drugs such as some anticonvulsants, cyclosporine, and sex steroids.
Tip: Chronic GH excess (as in acromegaly and heavy illicit use) enlarges visceral organs and the heart and is associated with increased mortality. There is no safe self-directed high-dose regimen; this library does not provide one.